CFO transition
Tenaya Therapeutics, Inc. CFO transition: Eric Hyllengren, M.B.A. to succeed Faraz Ali, M.B.A.
Tenaya Therapeutics, Inc. reported in a Form 8-K filed June 29, 2026 that Eric Hyllengren, M.B.A. will succeed Faraz Ali, M.B.A. as Chief Financial Officer, effective July 13, 2026.
In the filing's words
On June 29, 2026, Tenaya Therapeutics, Inc. (the “Company”) announced that Eric Hyllengren, M.B.A., will join the Company as Chief Financial Officer on July 13, 2026 (the “Commencement Date”), and in such capacity, will serve as the Company’s Principal Financial Officer and Principal Accounting Officer beginning on the Commencement Date.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Tenaya Therapeutics, Inc. (TNYA) |
|---|---|
| Event | Transition |
| Incoming | Eric Hyllengren, M.B.A. |
| Outgoing | Faraz Ali, M.B.A. |
| Title in the filing | Chief Financial Officer |
| Effective | July 13, 2026 |
| 8-K filed | June 29, 2026 |
| Internal promotion | Not established by the source |
| SEC CIK | 0001858848 |
Tenaya Therapeutics, Inc. reported this change in a Form 8-K, Item 5.02, filed June 29, 2026. The filing's own words are quoted above.
Other records naming Faraz Ali, M.B.A.
1The outgoing officer on this record, matched by name. Career line.
2026-03-11 · 10-K signature
Faraz Ali, M.B.A. signed Tenaya Therapeutics, Inc.'s annual report as Chief Executive Officer and Director (Principal Executive Officer and Interim Principal Financial Officer)
Same industry, June 2026
1Other moves filed that month at companies the roster files under SIC “Biological Products, (No Diagnostic Substances)”.
4 months ago· 2026-06-26InterimATRA
Atara Biotherapeutics, Inc. names Kevin G. Sarney interim CFO
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Eric Hyllengren, M.B.A.? Send a correction with the primary source.